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Skin autoimmune conditions belong to a larger group of connective tissue diseases and
primarily affect the skin, but might also involve underlying tissues, such as fat tissue,
muscle, and bone. Autoimmune antibodies (autoantibodies) play a role in autoimmune
skin diseases, such as localized scleroderma also termed morphea, and systemic
scleroderma, also called systemic sclerosis (SSc). The detailed studies on the biological
role of autoantibodies in autoimmune skin diseases are limited. This results in a few
available tools for effective diagnosis and management of autoimmune skin diseases.
This review aims to provide an update on the detection and most recent research
on autoantibodies in morphea. Several recent studies have indicated the association
of autoantibody profiles with disease subtypes, damage extent, and relapse potential,
opening up exciting new possibilities for personalized disease management. We discuss
the role of existing autoantibody tests in morphea management and the most recent
studies on morphea pathogenesis. We also provide an update on novel autoantibody
biomarkers for the diagnosis and study of morphea.
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INTRODUCTION
Being a part of an abnormal immune response, autoimmune antibodies (autoantibodies) are
valuable biomarkers in autoimmunity. The causality of autoantibodies in autoimmune diseases
is still controversial and requires more fundamental research (1). Nevertheless, clinical assays
detecting autoantibodies are commonly used to diagnose and categorize autoimmune diseases
(2). Recent studies have revealed distinct autoantibody profiles among patients with autoimmune
diseases, opening up new avenues for better diagnostics and personalized disease management (3).
The prototypical rheumatologic autoimmune disease of the skin, systemic sclerosis (SSc), is
often defined and subcategorized by an auto-antibody profile, in addition to the extent of skin
involvement (4). The presence of scleroderma-associated autoantibodies, such as autoantibodies to
topoisomerase and centromeres, has enabled clinicians to better predict organ system involvement
in these patients. Nevertheless, the true pathogenicity of these autoantibodies in SSc disease
propagation remains to be elucidated.
A “sister” autoimmune disease to SSc in regards to its similar effect on the skin is localized
scleroderma, also termedmorphea. Althoughmorphea and SSc share the same skin histopathologic
changes, the distribution and pattern of skin involvement, and the associated extracutaneous and
internal organ manifestations, are quite different (5). Morphea is typically distributed in patches
or bands of skin inflammation and thickness either on the head, extremity, and trunk in an
ipsilateral fashion (Figure 1). Based on the distribution patterns and depth of lesions, morphea has
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been divided into several clinical subtypes: circumscribed
superficial morphea (plaque morphea), superficial deep morphea
(deep morphea), generalized plaque morphea (multiple plaque
lesions), linear scleroderma of the trunk/extremities, linear
scleroderma of the head (also termed Parry–Romberg Syndrome
and En coup de sabre), and pansclerotic morphea or mixed
morphea (a combination of two or more of these subtypes)
(6). Although morphea does not tend to have internal organ
manifestations, such as interstitial lung disease or cardiac
arrhythmia, the underlying and associated tissue is often affected
in morphea patients, causing morbidity. The frequency of
extracutaneous involvement in morphea has ranged from 20 up
to 70% in the literature, depending on whether the data has
been collected retrospectively or prospectively, with prospective
assessment data capturing more manifestations (7–13). The
most common extracutaneous manifestations (ECM) across
cohorts are musculoskeletal, including arthralgia, arthritis, joint
contractures, myositis, fasciitis, with associated disease-induced
gait disturbance, decreased function, muscle, bone, and limb
atrophy (Figure 1), and followed by neurologic, ophthalmologic,
and dental issues occurring in ∼50% of morphea patients
with involvement of the head (14–16). These manifestations
include seizures, headaches, hemiparesis, cranial nerve palsy,
optic neuritis, uveitis, scleritis, dry eye, atrophic dental roots,
dental crowding, and malocclusion. Morphea subtypes and
ECM associations are different in adult vs. childhood-onset.
Circumscribed superficial (plaque morphea) and generalized
morphea are common in adult-onset morphea (Figure 1A),
while linear scleroderma, both linear trunk/extremity and linear
head subtypes, is more common in childhood-onset morphea
(Figure 1B) (10, 11). To achieve personalized management
schemes, these factors shall be taken into account.
In general, morphea is monitored clinically through the
visualization and scoring of skin changes over time (Figure 1).
Several clinical assessment methods have been developed
to monitor morphea, such as depigmentation, induration,
erythema, and the telangiectasia (DIET) score, the modified
Rodnan skin score (mRSS), and the Localized Scleroderma
Assessment Tool (LoSCAT) (12, 17). All of these methods
assess activity and damage together, based on selected clinical
parameters. The lack of a full validation of treatment response
criteria of these scores limits the ability of clinicians to judge the
effectiveness of these treatments. A combination of a cutaneous
outcome measure in conjunction with serological biomarkers,
such as autoantibodies, might be a plausible means to better
classify and stratify morphea patients.
With regard to serological testing, the role of autoantibodies
in morphea and their clinical application is not as clear as SSc.
So far, it is recommended to use the Localized Scleroderma
Assessment Tool (LoSCAT), with autoantibody tests when
concurrent rheumatic and other autoimmune diseases are
suspected. Suggested tests to verify this include antinuclear
antibodies (ANA), antibodies to single strandedDNA (a-ssDNA),
anti-histone antibodies (AHA), and anti-topoisomerase antibody
type of anti-nuclear autoantibodies (anti-Scl-70).
A particular limitation of the literature in regards to
autoantibody testing in morphea is that the majority of studies
reporting autoantibody positivity are in context of a larger
descriptive morphea cohort summary; therefore only a subset
of patients have available autoantibody testing, typically guided
by clinical practice instead of prospective research testing. To
address this limitation, we only included cohort studies in which
at least 50 morphea subjects were tested for the autoantibody
of interest, in addition to prospective studies designed to test
autoantibodies in morphea, to obtain more accurate frequencies
and clinical correlations.
The review is organized into three parts. First, we describe
the status with existing autoantibody tests (ANA, AHA, and a-
ssDNA) in the context of morphea diagnosis and treatment.
Here, the literature has been selected based on the number
of patients with a particular autoantibody tested within each
cohort (≥50 patients), and suggested associations with clinical
manifestations of the disease. In the second part, we present
the most recent studies on the role of autoantibodies in the
pathogenesis of morphea. Here, we selected studies that included
relevant controls and suggested pertinent new knowledge on
morphea pathogenesis. Third, we describe emerging biomarkers
in morphea research and clinical diagnostics; in this part, we
select the literature based on the statistical power of the observed
effects, and the appeal to potential personalized management of
morphea patients.
Besides a low number of enrolled patients, a large deviation
in the applied methodologies is another main problem in the
field of morphea diagnostics. Therefore, we critically assessed
the methodology for autoantibody testing, applied controls, and
standardization methods. We also discuss the problem of the
limited number of relevant animal models for morphea research,
and the connection between recent studies on the potential to
reveal new valuable insights into the pathogenesis of morphea,
and to improve the disease management in clinics.
LABORATORY DIAGNOSTICS OF
AUTOANTIBODIES IN MORPHEA
ANA Positivity in Morphea
Elevated antinuclear antibody (ANA) levels are often
encountered in morphea, with larger cohort reports
detecting 23–68% ANA-positive patients (see Figure 2;
Supplementary Table 1 and cited references). The majority
of studies (>80%) describe ANA testing by Human epithelial
type 2 immunofluorescence assay (Hep2 IF), with a cut-off of
>1:80 in most papers, run in standardized laboratory associated
with the ordering institution. Notably, both pediatric-onset
and adult-onset morphea have ANA positivity in this range
(Supplementary Table 1 and cited references). One cohort study
(Morphea in Adults and Children; MAC) reported a trend
toward higher ANA positivity in adults (53% vs. 30% pediatrics)
(10). However, in a later study with more subjects enrolled in
the MAC cohort, the frequency of ANA positivity was higher
in pediatric onset (27% in adults vs. 42% in pediatrics patients).
The largest cohort to date with ANA testing is an international
pediatric morphea cohort described by Zulian et al. in which 750
morphea patients were described, 671 in whom had ANA testing
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FIGURE 1 | Morphea: (A) Generalized morphea and plaque morphea are the most common subtypes of morphea in adult patients, while (B) linear scleroderma of the
trunk, limbs, and head are the most common in pediatric morphea. For each photograph, written informed consent was obtained from the participant for the
publication of this image.
performed (13, 18). Of these, 284 patients (42.3%) were ANA
positive. ANA positivity was tested among subtypes of morphea
(linear, plaque, generalized, and deep morphea) and there was
no significant difference (18), with subtype ANA positivity
ranging from 31 to 47%. ANA positivity has been debated to be
associated with the subtype of morphea, with the initial findings
of the MAC cohort supporting an association with generalized
morphea and mixed morphea (generalized + linear) (10). Their
later study using matched healthy case-controls compared to the
morphea cohort did not find an association of ANA positivity
with morphea subtype (19).
A metanalyses of ANA positivity was performed to more
formally capture the average ANA positivity in morphea patients
across various cohort publications. Our search strategy aimed
to identify studies that described antibody testing or cohort
reports in morphea (localized scleroderma). All studies that
reported antibody testing were reviewed (both retrospective
and prospective). Independent searches of the PubMed, Google
Scholar, and Webscope databases for relevant studies was
performed using the following search terms: morphea, localized
scleroderma, antibody, ANA, AHA, pediatric, rheumatoid factor
(RF), juvenile, morphea cohort etc. The search was limited to
studies that included 50 or more patients tested for antibodies
of interest. Citations were screened for duplicate studies and
duplicate patient samples without blinding. Statistics software
(MedCalc Software, Ostend, Belgium) was used for the statistical
analysis. Outcomes were measured by calculating proportions
and 95% confidence intervals (CIs) for each study, then pooled
the data to derive a pooled proportion and 95% CI.
For the purpose of proportion meta-analysis, the proportions
were first turned into a quantity (the Freeman-Tukey variant of
the arcsine square root transformed proportion) suitable for the
usual fixed and random effects summaries (20, 21). The pooled
proportion was calculated as the back transform of the weighted
mean of the transformed proportions, using DerSimonian
weights for the random effects model (22) in the presence of
significant heterogeneity. The impact of heterogeneity on the
pooled estimates of the individual outcomes of the meta-analysis
was assessed with the Cochran Q statistic and I2 test, which
measure the inconsistency between the study results, which was
interpreted as the approximate proportion of total variation in
the study estimates that was due to heterogeneity rather than
sampling error (23). I2 values of 25, 50, and 75% are considered
low, moderate, and high estimates, respectively (24). As the
Cochran Q test has a low sensitivity for detecting heterogeneity, a
P-value of < 0.1 was considered significant for the presence of
statistical heterogeneity (25). The presence of publication bias
was checked with the Begg funnel plot (26), which plots the
proportion (in the X axis) against the standard error of the
proportion (in the Y axis). In the absence of publication bias,
the proportion estimates from smaller studies are expected to be
scattered above and below the summary estimate, producing a
triangular or funnel shape.
The ANA positivity in primarily pediatric onset morphea
patients ranged from 5.9 to 68%. The pooled ANA positivity
was 29.9% (95% CI 27.3–32.5%) by the random effects model
(Figure 2). There was significant but low heterogeneity for
ANA positivity (I2 38.3%, Cochran Q statistic 16.2, P =
0.008). Subanalyses were performed in attempt to identify
patient characteristics or variables which may influence the
heterogeneity, such as sex and subtype. Female sex had non-
significant (p = 0.21) effect on the ANA+ heterogeneity. Age
of patient had a significant effect on ANA+ heterogeneity
(p = 0.0001), with the pediatric onset cohorts having more
consistent ANA+ frequency compared to adult cohorts.
When dichotomizing morphea subtype into linear (linear
extremity/trunk and head) vs. nonlinear (generalized, plaque,
deep morphea), there was also a significant impact on ANA+
which was more moderate with I2 68%.
Although not directly related to the morphea subtype, ANA-
positivity does seem to associate with disease severity in regards
to the depth of the disease, association with ECMs, as well as
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FIGURE 2 | Pooled ANA positivity in patients with morphea: (A) The ANA positivity (percentages) in the individual studies are represented by squares, through which
the horizontal lines represent the 95% CIs. The thick vertical line represents the pooled ANA positivity from these studies; (B) Funnel plot of the proportion vs. the
standard error of the proportion for ANA positivity. The circles represent the trials included in the meta-analysis. The line in the center indicates the summary
proportion. The other lines represent the 95% CIs. Asymmetry about the pooled proportion line is consistent with the presence of minimal publication bias.
with the probability of the disease flare after remission. A study
of a large pediatric international cohort (n = 750) reported
a significant association of extracutaneous manifestations with
ANA positivity (13). In this cohort, there were 168 patients
(22%) with ECMs, the most common being articular (47%),
followed by neurologic, vascular, ocular, and autoimmune
(13). When comparing skin involvement with extracutaneous
involvement subjects, the authors also noted that the erythrocyte
sedimentation rate, C-reactive protein, creatinine kinase, serum
IgG, and rheumatoid factor were significantly elevated in
those with ECMs. Rheumatoid factor has been measured by
ELISA; other clinical tests were done following standard clinical
procedures utilizing pre-determined normal range for the age of
the patient per test. Noteworthy, each of these laboratory tests
was available for at least 350 patients, which is a limitation of
several other studies. The authors argued that the positive ANA
in morphea patients might be associated with either deeper tissue
involvement or with a more immunogenic or true “systemic”
autoimmune disease. The latter is typically associated with a
myriad of positive immune activation markers (ANA, ESR, CRP,
IgG, and other autoantibodies discussed next).
Data from the second largest morphea cohort published,
the Childhood Arthritis and Rheumatology Research Alliance
(CARRA) North American registry cohort of 381 pediatric
morphea, supports the notion of ANA positivity corresponding
to deeper tissue involvement (14). Using IF on Hep-2 cells,
standard laboratory evaluation and cut-off, the Childhood
Arthritis and Rheumatology Research Alliance (CARRA) cohort
demonstrated 48% ANA positivity with a significant association
of non-cutaneous disease damage with ANA, specifically
for the deeper tissues of the extremity with remaining
joint contractures, muscle atrophy, and extremity shortening
(Supplementary Table 1) (14). In addition to the depth of the
disease into adjacent connective tissue, ANA positivity has also
been associated with cutaneous disease extent. The MAC cohort
based in Texas (USA) and the National Registry of Childhood
Onset Scleroderma (NRCOS) based in Pittsburgh (USA) both
found that the extent of this skin disease (body surface area,
number of lesions, number of areas affected, and mRSS) to be
significantly associated with ANA positivity (19, 27). Similar
to CARRA, the MAC cohort was tested using IF on Hep-2
cells, internal laboratory quality control, and healthy controls.
Interpretation of the results has been standardized using a serum
dilution series on the cells, and automated data processing to
exclude the interlaboratory deviation.
In a prospective clinical cohort, the NRCOS, with full
longitudinal data available from 77 morphea patients and
an average follow-up of 5 years, a positive ANA at the
baseline visit increased the odds of relapse (after obtaining
remission) by a factor of 4.8 (95% CI [1.37–17.2]) (28).
The same group more recently studied ANA positivity and
more classic SSc-related autoantibodies in the NRCOS cohort
(Supplementary Table 1). Utilizing an ANA cut-off of 1:160 via
indirect immunofluorescence (IF) on Hep2 cells, 50% (35/69)
pediatric morphea patients had ANA positivity, with one-
third having 1:160 titer and decreasing percentages as the titer
level increased, but as many as 11% had a titer of 1:1520.
The most common pattern was speckled (50%), followed by
homogenous, nucleolar, and centrosome (29). A panel of SSc-
associated autoantibodies, including anti-topoisomerase (Scl-
70), anti-centromere, U3RNP, and PM-Scl, was evaluated on
all 69 subjects and were all found to be positive for 6–16%
of the morphea subjects. The FIDISTM Connective Profile SSc
line immunoassay (LIA) (Euroimmun, Germany) and MagPix R©
(LuminexTM) addressable laser bead immunoassay (ALBIA) were
used to analyse morphea subject sera positivity in relation to
age and sex matched healthy pediatric controls [cut-off two
standard deviations (SDs) above the mean]. In general, when
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positive, these SSc-associated autoantibodies did not signify the
diagnosis of SSc or the internal organ manifestations typically
associated with SSc but correlated with morphea disease severity,
such as joint contractures, musculoskeletal involvement, and
skin symptoms of tingling, pain, and skin thickness (29). This
supports the hypothesis that morphea (localized scleroderma) is
“not just a skin disease” but that it is truly an autoimmune disease
with circulating autoantibodies, associated with deeper tissue
disease and more extensive connective tissue disease (28, 29).
The significant correlation of ANA and associated extrable
nuclear autoantibodies with the depth of tissue involvement,
extracutanous manifestations and potential for relapse in
morphea, places ANA as a potential biomarker for morphea
disease stratification and management, either individually or as
a composite indictor with clinical variables, such as the mLoSSI,
and other immune markers, such as cytokines of interest in
the field, CXCL9 and CXCL10 (30, 31). CARRA investigators
support ANA positivity in the prediction of muscle involvement,
as is was associated with muscle atrophy, joint contracture
and/or limb shortening, along with elevated muscle enzymes,
CPK and aldolase, in a large North American cohort (32). A
positive ANA at the baseline clinical visit for a morphea patient
should prompt the clinician to closely monitor (1) the depth of
the lesion, which may include further evaluation with MRI of
the fascia, muscle, tendon and joint, especially the linear and
generalized plaque morphea subtypes (33, 34), and (2) clinical
signs of disease relapse, both during quiescent disease while on
treatment and after systemic treatment course is completed (28,
35). The design of clinical trials for morphea are currently under
discussion, with inclusion of ANA and other autoantibodies as
exploratory biomarkers.
Anti-histone and ss-DNA Antibodies
in Morphea
In an original report of a Japanese cohort studied in the
1990s (36), anti-histone antibodies (AHAs) were positive in 47%
(23/49) of the cohort. This was studied by immunoblotting and
ELISA, using manual data processing, internal quality control,
and a titration curve from certified tests for quantification
purposes. AHA titers correlated positively with the number of
lesions, larger distribution of lesions, and muscle involvement.
More recent large cohort analyses in North America and Europe
have also studied AHA positivity in morphea and have found
similar associations (Figure 3; Supplementary Table 2). A North
American nested case-control study, including both pediatric
and adult morphea subjects (n = 187) and age, sex, and race-
matched controls (n = 149) who were all tested for AHA via
ELISA, found a significant difference in AHA positivity between
morphea subjects and controls (12 vs. 2%, p < 0.001) (19). AHA
positivity was more frequently present in the linear morphea
subtype compared to the generalized plaque morphea (18 vs.
7%, p = 0.04) (19). The AHA may indeed associate with the
linear morphea subtype, as the other large North American
cohort, the NRCOS, consisting of 60% patients with linear disease
subtype, reports a relatively high AHA positivity (32–39%) in a
longitudinal study of subjects (30, 38). Consistent with original
findings in Japan (36), in this North American cohort, AHA
correlated with general disease burden, such as number of lesions
and number of sites with skin involvement, especially if ≥ two
cutaneous sites (as dictated by the LoSCAT score) were affected.
AHA levels also correlated with the depth of the lesion, reflected
by the presence of joint contractures (27, 30, 38). Although the
AHA seemed to predict severity, it was not found to be a predictor
of disease relapse prospectively in the NRCOS cohort (28).
Interestingly, in NRCOS, the AHA levels did have some
immunological correlation to T-helper (TH) cell-associated
cytokines evaluated by Luminex, including TH1-associated
cytokines (IL-12p70, IFN- γ, IL-2), TH2-associated cytokines
(Il-4, IL-13), and TH17 associated cytokines (IL-17a, IL-17e,
IL-17f, IL-d22, IL-23) (37). The Luminex assay has been
standardized using age-matched healthy controls and internal
laboratory quality control. Sensitivity down to a couple of
molecules/uL samples is a great advantage of a Luminex
detection methodology; in addition, all data have been processed
automatically. Immune activation, reflected by cutaneous disease
activity, was noted in this cohort’s earlier reports, with a subset
of patients having longitudinal changes in their AHA levels
corresponding to changes in the disease activity status (38).
Around the same time the AHA was being described in
morphea, the research group in Pittsburgh identified an antibody
to DNA in morphea. Originally it was thought to be directed
to double-stranded (ds) DNA, but an investigation with the
Crithidia lucillae IF assay determined negative antibodies to
double-stranded DNA (a-dsDNA), but a positive anti-single
stranded DNA (a-ssDNA) antibodies (27). Herein, internal
laboratory control and a non-matched healthy cohorts were
applied, and the data was processed automatically. Further,
the study of 39 patients in this cohort found that 51% of
the morphea subjects had positive anti-ssDNA, with a positive
correlation between anti-ssDNA antibody and joint contracture
or active disease with a duration of longer than 2 years (27)
(Supplementary Table 2). These general findings were validated
in a Japanese cohort, led by Takehara and Sato, who found
50% morphea subjects with a positive anti-ssDNA, which
correlated with deeper involvement of the muscle and fascia
(39). Anti-ssDNA levels also correlated positively with the
disease activity in a subgroup of patients (39). Later studies
in the childhood-onset Pittsburgh cohort, NRCOS, continued
to find anti-ssDNA positivity in ∼30–44% of their morphea
subjects, associated with more extensive skin involvement,
active disease, and inflammatory cytokines IFN-α2 and IL-33,
signifying immunologically active disease (30, 38). Noteworthy,
anti-ssDNA positivity did not predict relapse in this cohort
followed longitudinally (28).
Double positivity for AHA and anti-ssDNA was associated
with a more severe morphea phenotype with deep tissue
involvement and joint contracture, especially in childhood-onset,
but also adult onset (38). In contrast, the other North American
cohort, MAC, found a much lower positivity of anti-ssDNA,
finding 6–8% positivity among combined adult and pediatric-
onset morphea, which was not significantly different from their
control cohort (7%) (19, 40). It is unclear why there is a degree of
difference, potentially due to the different testing methods (41),
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FIGURE 3 | General overview of morphea autoantibodies in relation to clinical features. Anti-ssDNA, Anti-single stranded DNA; IFNx, Interferon; ILx, Interleukin; SSA,
Sjogren’s-syndrome-related antigen A; SSB, Sjogren’s-syndrome-related antigen B; Scl-70, Topoisomerase I; ACA, Anti-centromere antibody; ECM, Extracutaneous
manifestations; SSc, Systemic Sclerosis; SLE, Systemic lupus erythematosus; GM-CSF, Granulocyte-macrophage colony-stimulating factor; VEGF, Vascular
endothelial growth factor; Ab, Antibody (9, 10, 13, 18, 19, 27–30, 37, 38).
ELISA compared to IF. IF is believed to be more accurate. IF
also has an automated data processing vs. the often manually
performed ELISA.
In the dermatology-based United States cohort, the MAC
cohort, patients with a double positivity for ss-DNA and AHA
or ANA, indicated more severe morphea including functional
limitations in linear disease (anti-ssDNA, p = 0.005; and AHA,
p = 0.006), extensive body surface area involvement (anti-
ssDNA, p = 0.01; and ANA, p = 0.005), and higher skin damage
(ANA, p= 0.004) (19).
In concert with the ANA’s ability to reflect deeper disease,
such as fascia, muscle, and joint involvement, with resultant joint
contractures, AHA and ss-DNA positivity share this relationship
and could guide the clinician’s management. This would include
a more complete examination of the underlying connective tissue
with a thorough joint examination and the use of available
adjunct measures to monitor the depth and activity status
of morphea in deeper tissues, such as MRI and Ultrasound
(33, 34). A combination of positive antibodies between ANA,
AHA, and ss-DNA should signify to the clinician a more
severe immunophenotype with potential progression to joint
contracture, which may influence decisions to initiate systemic
medications and the length of treatment. Unlike ANA positivity
at the baseline assessment, AHA and anti-ssDNA antibodies do
not appear to influence disease relapse to assist in assessment
of recurrence.
Systemic Sclerosis and Systemic Lupus
Erythematosus Autoantibodies in Morphea
Antibodies against the traditional extractable nuclear antigens
(ENAs), such as anti-dsDNA, SSA/B, Smith/RNP, anti-Scl-
70, and anti-centromere Abs, are seldom in morphea, with
general percentages of positivity ranging from 1 to 15%
internationally in both pediatric and adult onset morphea
[Supplementary Table 3; (9, 10, 13, 18, 29)]. These serum
autoantibodies were obtained clinically, and abnormal values
were referenced to the normal range of laboratory parameters
of each of the participating centers. It is important to note
that clinical development of the connective tissue diseases
typically associated with these ENAs, such as SLE, Sjogrens’
or SSc, was not documented in any of these cohort studies
(Supplementary Table 3). Only a few studies investigated clinical
associations of morphea patients with these ENAs. The
international pediatric cohort compared morphea subtype and
presence of extracutaneous manifestation with the presence
of ds-DNA, Scl-70, and centromere antibodies and did not
find any associations (13, 18). However, in the prospectively
collected NRCOS cohort, when comparing detailed clinical
variables of morphea, such as lesion characteristics of thickness,
subcutaneous atrophy, and patient symptoms, such as pain at site
of the lesion, more correlations were detected with these ENAs
(Supplementary Table 3) (29).
Frontiers in Immunology | www.frontiersin.org 6 July 2019 | Volume 10 | Article 1487
Khatri et al. Autoantibodies in Morphea: An Update
Rheumatoid Factor
Rheumatoid factor (RF), which is typically associated with adult
rheumatoid arthritis, was positive in 3–16% of morphea patients
in the reported cohorts internationally (Supplementary Table 3).
These serum RF values were obtained clinically, and abnormal
values were referenced to the normal range of laboratory
parameters of each of the participating centers. The largest cohort
tested were childhood-onset patients (n = 464). Of this cohort,
16% of subjects were RF positive which correlated positively
with arthritis and musculoskeletal manifestations (18), providing
evidence for increased clinical monitoring of the joints of positive
RF patients (42–44).
ROLE OF AUTOANTIBODIES IN THE
PATHOGENESIS OF MORPHEA
There are several recent studies aimed at an improved
understanding of the basic biology of morphea. A better
understanding of the underlying mechanisms in morphea,
especially during the active inflammatory phase, would lead to
more direct and efficient therapies (45). According to Jacobe
et al. specific HLA class I and class II alleles are associated
with generalized and linear subtypes of morphea (40). Notably,
the morphea-associated alleles are different from those found
in SSc, suggesting that morphea is immunogenetically distinct.
Risk alleles in morphea are also associated with conditions such
as rheumatoid arthritis (RA) and other autoimmune conditions
(40). The role of HLA products in regulating interactions of
immune cells is well-known (46), and therefore, the specific
HLA profile of morphea could lead to B cells producing
certain cytokines and autoantibodies contributing to disease
progression (40, 47).
Cytokine and autoantibody profiles and their relationship
to clinical features in morphea have been described. It is
believed that the imbalance between Th1/Th2/Th17 cell subsets
drives inflammation in the early stages of disease (Th1 and
Th17 predominant) and fibrosis in the later stages of morphea
(Th2 predominant) (47). As in SSc, T-helper (Th) cells and
their associated cytokines have been suggested to contribute
significantly to the pathophysiology of the disease. This was
confirmed by the presence of cytokines from Th cells in the sera
and tissues of patients (Figure 4) (37).
Kurzinski and Torok analyzed the available experimental data
on cytokines in morphea and compared them to available clinical
disease severity and activity features (37). They confirmed that
cytokines of Th1, Th2, and Th17 cell responses likely contribute
to the pathogenesis of both SSc and morphea. Prior studies
support the theory of Th1/Th2 imbalance in SSc propagating
disease in a Th2 manner, leading to skin fibrosis and damage.
Early presence of the pro-inflammatory cytokines IL-2 and IL-
6 inducing Th17 in morphea patients suggests that an early
increase of Th1 cytokines mediates the active, inflammatory
phase of the disease (which was further supported by their later
work) (30), and the subsequent inflammation and transition to
the fibrotic damage phase is achieved via Th17. This is further
supported by the elevated Th17 effector cytokines 2–4 years
after the initial onset of disease. In turn, Th2 effector cytokines
shown to be present at elevated levels in morphea promote the
development of tissue damage and fibrosis later in the course of
the disease (37).
Badea et al. reviewed step-wise development of morphea
(Figure 4) (48). In early inflammatory stages, environmental
stimuli and genetic factors activate mononuclear cells that in
turn induce perivascular infiltration of the skin. At this stage,
ANA, cytokines, and other soluble cell-adhesion molecules are
elevated, confirming on-going immune activation. At stage 2,
functional and structural changes occurred to the microvascular
system, and adhesion molecules including ICAM-1 and VCAM-
1, were upregulated in response to various cytokines and cell
mediators (IFN-γ, IL-1, TNFs). The third stage is the least
understood, and it is believed to involve a large release of
cytokines by the lymphocytes. IL-4, IL-6, and IL-8 are among
those overproduced cytokines. Stage four involves hardening
of the skin from excessive cellular proliferation and deposition
of collagen and other extracellular matrix components. This
stage of LS progression has the most deleterious effects and is
believed to be driven by excess IL-4 and TGF-β (48). This general
pathogenesis model has been confirmed by in vitro studies in
cohorts of morphea patients at different disease stages, and by
knock-out mouse models (Tsk). Using novel antigens in vivo
could bring new insights into pathogenesis. Moreover, detailed
studies of T and B cell populations in morphea vs. controls, e.g.,
SSc and psoriasis, are lacking (49).
Osmola–Mankowska et al. added new knowledge to the
existing picture of morphea pathogenesis, by proposing the
underseen role of dendritic cells (DCs) in it (Figure 4) (50). In
brief, an unknown natural ligand activates DC to produce IFN-
α and IFN-β that in turn activate myeloid DCs (mDCs). mDCs
activate autoreactive B and T cells via MHC molecules, which
then leads to skin autoimmunity and morphea in particular.
The hypothesis has been confirmed by both in vitro and in
vivo studies and is an exciting new knowledge with potential
therapeutic outcomes (50). T-cell subtyping has been successfully
used to identify in vivo the regulatory pathways associated
with morphea, specifically, confirming that apoptotic bodies
bearing CD8, activate CD205 of DCs. This knowledge allows
the application of already existing therapies to morphea, such
as pDC regulating SLE drug candidates (Anti-BDCA-2 Abs
and nanobodies).
Verification of the role of autoantibodies in morphea is
complicated by only a few available animal models. Marangoni
et al. reviewed available models of scleroderma (51) and
provided details on nine key mouse models available today,
created by exogenous administration of fibrosis-inducing agents
(bleomycin, Ad-TGFβ1223/225), and by genetic manipulation
(e.g., Tsk-2 and Fbn-1 mutants). The high diversity of skin
disease symptoms complicates creating a reliable model for
morphea. The authors suggest using genome-wide expression
analysis to match the animal models to the appropriate subtypes
of human clinical disease. Additionally, there is a high deviation
in methodology for inducing scleroderma pathogenesis with
bleomycin and Ad-TGFβ1223/225 that remains unresolved. In
spite of this, mouse models of cutaneous fibrosis are proven to
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FIGURE 4 | Biological mechanisms involved in morphea, and suggested roles of cytokines and autoantibodies.
be useful to study underlying mechanisms of the disease and its
linkage to other conditions (51).
Several other mouse models of skin fibrosis were reported
as useful to study the onset of the disease (52). Tsk1 and
Tsk2 models are developed through mutations in fibrillin gene
FBN1 leading to fibrinogenesis. It is known that fibrillin-1 is a
component of connective tissue microfibrils and is important
in correcting elastic fiber assembly. Second, fibrillin-1 can
partially control TGF-β availability via confirmed interactions
with TGF-β binding proteins 1 and 4. Genetic analysis of 6-
week-old Tsk mutant mice indicated morphea related effects:
upregulated collagen synthesis, increased bone morphogenic
protein, and connective tissue growth factor. Additionally, Wnt
signaling proteins that interfere with TGF-β are overproduced.
With regard to serology, 88% of Tsk mutant models are ANA
positive, and also contain AHA, anti-Scl-70, and anti-RNApol II
antibodies (52). This makes Tsk models potent tools for studying
autoantibodies inmorphea. A limitation is the fact that Tskmodel
lacks inflammation histologically, therefore it reflects SSc skin
condition more than morphea skin. Bleomycin-induced mouse
is an alternative to Tsk for studies of morphea which develops a
skin inflammation and a set of autoantibodies (51, 52).
EMERGING AUTOANTIBODY
BIOMARKERS IN MORPHEA
Autoantibodies to the dense fine speckled 70 kDa antigen
(anti-DFS70) is a hot topic in autoimmune research and
diagnostics at the moment. Anti-DFS70 are reported to be more
common in individuals who do not have an antinuclear antibody
(ANA)-associated rheumatic disease (AARD) than in patients
with AARD. So far, the frequency of anti-DFS70 antibodies
has been thoroughly studied in adults but not in pediatric
populations. The primary objective of a recent observational
study was to determine the frequency of anti-DFS70 in pediatric
AARD including morphea, and reference cohorts (53). Sera
from 743 children with AARD and related conditions and
345 samples from controls [healthy children and suspected for
AARD] were tested for anti-DFS70 antibodies. Using a novel
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FIGURE 5 | Synthetic DNA, RNA, and LNA antigens in morphea (56). (A) A general approach to the design including computation, library screening, and ELISA;
(B) representative molecular dynamics result for dsDNA antigen and autoantibody showing key interactions contributing to the binding; (C) Representative antigens
selected for the study of the pediatric morphea cohort, and correlations of ELISA results with modified localized scleroderma skin severity index (mLOSSI), index of
disease damage (LOSDI), and time in treatment. C1 and C2 were commercial controls used in the study, calf thymus DNA, and G-quadruplex human DNA.
chemiluminescence assay, anti-DFS70 antibodies were elevated
in 2.1% of healthy children and 4.5% of sera from ANA positive
pediatric samples. Information on standardization procedure was
missing for anti-DFS70 that might lead to deviation from other
cohorts. Notably, in line with previous studies which suggest
an overlap of morphea with other diseases, the frequency of
anti-DFS70 was highest in juvenile morphea (13.8%), along with
juvenile dermatomyositis (18.2%), childhood SLE (5.7%), and
juvenile idiopathic arthritis (2.5%) (53).
In our recent study, we developed a series of synthetic
oligonucleotides (54, 55) that allowed us to investigate the
details on the antigen recognition by autoimmune antibodies in
pediatric morphea (Figure 5) (56). In this work, we hypothesized
that having a sequence-controlled rationally designed DNA,
RNA, and locked nucleic acid (LNA) antigen might provide
new insights into sequence-specific binding of anti-ssDNA and
anti-dsDNA. Typically used in nucleic acid diagnostics and gene
therapy (57, 58) synthetic oligo- and poly-nucleotides are poorly
explored in immunology. However, these molecules have major
advantages of high purity, controlled chemical content and a
possibility to incorporate functional tags (54, 55). To design
new antigens which were 21–63 nucleotide long oligo- and
polymers, we successfully combined computation and library
screening (56, 59). The study has been benchmarked to SLE (n
= 30) and healthy controls (n = 80); standardization has been
done using internal laboratory control and external calibrators
provided by Odense University Hospital, Denmark, and Stanford
University Hospital, CA, USA. Besides dramatically improving
the analytical specificity of the assay, our data suggest a potential
link between antibodies to DNA and the disease state in
morphea. Moreover, introducing chemical modification (LNA)
into antigens completely changed the binding of corresponding
antibodies and their clinical relevance. The strongest observed
effect was seen for the localized scleroderma skin damage index
(LoSDI) on the IgG antibodies to TC dinucleotide-rich dsDNA
(p < 0.001) (56). Synthetic DNA and analogs are therefore
a new promising class of antigens that could bring light into
sequence specificity of anti-DNA antibodies in morphea and
related diseases. Lack of confirmation for antigen-antibody
reactivity in a relevant morphea animal model is a limitation of
this work.
Looking for gene association of autoimmune diseases
including morphea is a rapidly developing research field with
high potential to provide new insights into pathogenesis and
new biomarkers. Earlier, Torok et al. reported an up-regulated
IFN-related gene CXCL10 in pediatric morphea subjects (30).
Simultaneously, O’Brien et al. investigated transcriptional and
cytokine profiles in 87 adult morphea subjects and 26 healthy
controls (31). This study identified a disease severity association
for CXCL9, which was present at increased levels in active
morphea subjects (37%) along with Th1 cell cytokines (57%).
Related gene CXCL10 was upregulated in 44% morphea subjects
but did not correlate with disease severity (31). CXCL9/10 studies
also led to a new hypothesis on the onset of morphea. As
a result of cutaneous overproduction of IFN-γ by cutaneous
macrophages, Th1 imbalance in the skin could be a contributing
factor to disease progression. Thus, local skin autoimmunity
could be the driver of the disease in contrast to the systemic
dysregulation in SSc (31). In (31), a higher number of healthy
controls and additional disease controls could be included to
support this study.
CONCLUSIONS
As this review summarizes, morphea (localized scleroderma) is a
complex disease with a diverse profile of clinical manifestations
and still unresolved issues with serological diagnosis,
clear knowledge on pathogenesis, and missing of effective
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management routes. In this scoping review, we selected studies
based on the number of enrolled patients with autoantibody
testing (≥50 patients), relevance to studies of morphea
pathogenesis, and reported emerging animal models and
biomarkers that could lead to improved personalized morphea
management. Up to 50% of patients in cohorts described herein
have elevated levels of three main autoantibodies: ANA, AHA,
and anti-ssDNA, whereas other autoantibodies are observed at
frequencies below 10%.
These autoantibodies associate with more severe disease,
including lesion depth and spread, associating with more
severe morphea subtypes and extracutaneous manifestations.
The presence of two or more of these autoantibodies appears to
have a cumulative effect on correlation to disease affecting the
deep muscle, fasica and tendons, resulting in joint contracture
and limited mobility. Rheumatoid factor also appears to be a
strong indicator of deeper tissue disease with arthritis association.
Taken together, patients with ANA, AHA, ss-DNA, or RF
positivity in isolation, or more importantly in combination, are
at higher risk for muscle and joint morbidity. Extra care should
be taken to ensure these patients have a detailed musculoskeletal
examination (in addition to a thorough cutaneous assessment),
and if possible, consider imaging deeper tissue to monitor the
depth of moprhea involvement and the disease activity status
(i.e.,–edema of the fascia on MRI).
Furthermore, morphea patients with multiple autoantibody
positivity might have a more robust B cell activation, promoting
such antibodies, and may benefit from anti-CD20 therapy, such
as Rituximab, currently available for rheumatoid arthritis and
other connective tissue disease indications (60). Only a few
case reports are available evaluating Rituximab in morphea,
but do show successful response (including improvement of
deeper tissue via MRI evaluation) in previous recalcitrant
disease (61, 62). Another potential therapeutic target in morphea
is between the T cell and antigen presenting cell (DC or
B-cell) communication, via abatacept, a fusion protein that
inhibits CD80/86 interaction with CD28. This can dampen B
cell:T-cell interactions and T-cell functional activation, which
in turn would lead to less inflammatory driven fibrosis and
potentially less auto-antibody production. A few cases reports
have described successful treatment of morphea with abatacept,
especially widespread disease or deeper disease (monitored by
MRI in some) (63–65). Further clinical studies in trial format
are warranted to further understand the utility of these biologic
agents in treating morphea.
Pathogenesis of morphea remains being a black box, although
there are several recent works that bring new knowledge to the
field. The reported association with HLA I and HLA II alleles
defined by Jacobe et al., could be a breakthrough in the genotype
based diagnosis, subtyping and research on morphea (40).
Genomic association with CXCL9 is another exciting direction
toward these goals (31). Recently, a role of DCs in the critical
step of morphea development has been recently confirmed (50).
Tsk animal models show high levels of autoantibodies and similar
fibrotic skin features to human morphea, making Tsk mouse a
valuable model for further studies, although the inflammatory
state is somewhat limited in the Tsk mouse (51, 52). As more
information is gained about the underlying mechanisms of
morphea, diagnosis and treatments can become more accurate
and better personalized. Importantly, improving scleroderma
patients’ early diagnosis before extracutaneous manifestations
occur should improve patients long term recovery (45, 66).
Furthermore, beneficial autoantibodies having protective
effects against the development of immune-mediated diseases
and conventional antibodies depend on the activation of T and
B lymphocytes by antigen presenting DCs and share common
ontogeny (67, 68). Thus, it is suspected that the disturbance
in the homeostasis of autoantibodies can trigger autoimmune
diseases. Cabral-Marques reported that dysregulation of
autoantibody-targeting G protein-coupled receptors (GPCRs)
can trigger the development of rheumatic diseases including
rheumatoid arthritis and SSc. Sera from 84 patients with SSc
and 491 healthy controls were tested for anti- GPCRs antibodies.
Using commercial solid-phase sandwich ELISA, anti-GPCRs
concentration were either elevated or decreased in sera of SSc
and rheumatoid arthritis in contrast to healthy samples. Hence,
the discovery of anti-GPCR autoantibodies in pathogenesis
of rheumatic diseases opens up opportunities for new
investigations in autoimmune diseases including morphea and
SSc (68).
The potential impact of synthetic biology and computational
chemistry in improving the efficacy and specificity of existing
antigens might present an exciting new approach in the
management of morphea. For example, a combined computation
and library screening provided with a new TC rich dsDNA
antigen that allows for detecting autoantibodies associated with
skin damage index.
Increased evidence shows that environmental factors and
other diseases may have an impact on morphea. Emerging
biomarkers including anti-DFS70 and anti-LNA/DNA, aim at
detecting these associations, which opens up new pathways for
managing difficult and rare cases of morphea (69, 70).
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